Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Fierce 50
Special Report
Awards Gala
Awards
CRO Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Merck pays $9.2B for owner of flu antiviral J&J rejected
Merck & Co. is spending $9.2 billion for Cidara Therapeutics and its lead influenza antiviral that was dropped by Johnson & Johnson last year.
James Waldron
Nov 14, 2025 8:25am
Sponsored
Medicus pharma advances Teverelix in prostate cancer and urology
Nov 10, 2025 8:00am
BMS-J&J blood thinner fails phase 3, denting blockbuster hopes
Nov 14, 2025 8:10am
Sponsored
Addressing Choline Deficiency in Parenteral Nutrition Patients
Nov 10, 2025 8:00am
Sensei shrinks workforce by 65% as layoff warning comes to pass
Nov 14, 2025 10:33am
Ovid eyes next chapter with CEO transition—Chutes & Ladders
Nov 14, 2025 8:30am
More News
Fierce Biotech Layoff Tracker 2025: Kite, Ventus & more
Nov 14, 2025 7:00am
Analysts skeptical Applied can bring rare disease drug to market
Nov 14, 2025 5:25am
European VC Medicxi closes €500M biotech fund
Nov 14, 2025 3:00am
AbbVie to end Calico collab, lay off scientists: Stat
Nov 13, 2025 3:59pm
See more stories
